---
title: "Mounjaro (tirzepatide) in type 2 diabetes: Indication questions"
description: "Indication questions on Mounjaro (tirzepatide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Mounjaro approved for? Is Mounjaro approved for weight loss? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/indication"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Mounjaro (tirzepatide) in type 2 diabetes: Indication questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Mounjaro](https://uspl.lilly.com/mounjaro/mounjaro.html#pi)

Indication questions that apply to every indication of Mounjaro are on [Mounjaro (tirzepatide), all indications: Indication](https://www.evicenter.com/medical-information/mounjaro/indication).

## Indication

<a id="mounjaro-indication"></a>

### What is Mounjaro approved for?

> “MOUNJARO® is indicated:”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=MOUNJARO%C2%AE%20is%20indicated%3A)

> “as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=MOUNJARO%C2%AE%20is%20indicated%3A-,as%20an%20adjunct%20to%20diet%20and%20exercise%20to%20improve%20glycemic,with%20type%202%20diabetes%20mellitus.)

> “to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=2%20diabetes%20mellitus.-,to%20reduce%20the%20risk%20of%20major%20adverse%20cardiovascular%20%28CV%29%20events,high%20risk%20for%20these%20events.)

<a id="mounjaro-weight-loss-indication"></a>

### Is Mounjaro approved for weight loss?

> “Mounjaro is not indicated for weight loss.<sup>2</sup> Weight-related changes were secondary endpoints.<sup>2</sup>”

Source: [MOUNJARO: Mounjaro® (tirzepatide) | GIP and GLP-1 Receptor Agonist for T2D, captured 2026-11-12](https://mounjaro.lilly.com/hcp#:~:text=Mounjaro%20is%20not%20indicated%20for,Weight%2Drelated%20changes%20were%20secondary)

## Related pages
- [Medical information: Mounjaro (tirzepatide): Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes)
- [Clinical trials](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/safety)
- [Specific populations](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/access-and-coverage)
